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ABSTRACT
The concept of chronic kidney disease–mineral bone dis-
order (CKD-MBD) does not appear to fulﬁl the requirements
for a syndrome at ﬁrst glance, but its deﬁnition has brought
some clear-cut beneﬁts for clinicians and patients, including
wider and more complex diagnostic and therapeutic ap-
proaches to the management of this challenging set of issues.
Admittedly, not all components of CKD-MBD are present in
all patients at all times, but these are highly interrelated, in-
volving mineral and bone laboratory abnormalities, clinical
and histological bone disease and ﬁnally, cardiovascular
disease. The presence of typical biological bone ossiﬁcation
processes in an ectopic anatomical location in CKD has
helped to deﬁne the existence of an unprecedented bone–
vascular relationship, extending its interest even to other
medical specialities. For now, we believe that CKD-MBD
does not reach full criteria to be deﬁned as a syndrome.
However, this novel concept has clearly inﬂuenced current
clinical guidelines. The National Kidney Foundation Kidney
Disease Outcomes Quality Initiative (NKF/KDOQI™)
guidelines in 2003 for instance recommended that calcium-
based phosphate binders should be avoided to treat
hyperphosphataemia in the presence of cardiovascular calci-
ﬁcations. In 2009, the KDIGO and other guidelines
reinforced and extended this recommendation by stating that
it is reasonable to choose oral phosphate binder therapy by
taking into consideration other components of CKD-MBD.
Similarly, it is also considered reasonable to use information
on vascular/valvular calciﬁcation to guide the management
of CKD-MBD. Our current assumption as a working group
‘CKD-MBD’ is that CKD-MBD has the potential to be
deﬁned a true syndrome, such as a constellation of concur-
rent signs and symptoms that suggest a common underlying
mechanism for these components as opposed to the term
disease. The term ‘syndrome’ also implies that in any patient
at risk due to the presence of one or a few components of the
entire syndrome, the screening for additional components is
highly recommended. However, it has not currently been de-
monstrated that there is an additive predictive value, which
can be derived from identifying individual components.
Despite all we have learned about this putative syndrome, we
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have been left with only a hypothetical framework about how
to treat patients. So while we agree that the concept of CKD-
MBD has inﬂuenced, and continues to inﬂuence, our current
clinical hypotheses, deﬁnitive proof of a beneﬁt of interven-
tions in CKD-MBD is still lacking and a global–multiple
therapeutic approach to treat simultaneously several com-
ponents of CKD-MBD should be tested by well-designed
new randomized controlled trials.
Keywords: syndrome, chronic kidney disease, parathyroid
hormone, cardiovascular outcome, renal osteodystrophy
INTRODUCTION: WHY IS THE DEFINITION
OF CKD-MBD RELEVANT?
The term ‘syndrome’ comes from the ancient Greek ‘συν-
δρομή’ indicating something ‘running or occurring together’
(from συν or ‘syn’ = ‘along with or together’, and δρομή or
dromos = ‘course or race’). In medicine, it indicates a speciﬁc
constellation of concurrent signs and symptoms that suggest a
common underlying mechanism for these components. Thus,
a syndrome may have several items and causes as opposed to
the term ‘disease’, which refers to a cluster of signs and symp-
toms with a deﬁnite single cause.
In recent years, laboratory abnormalities are frequently
employed as surrogate markers for risk exposure at the popu-
lation level, such as cholesterol for cardiovascular risk, glycated
haemoglobin for risk of diabetes-associated events, ﬁbrotest for
liver disease risk, proteinuria/albuminuria for risk of progression
of chronic kidney disease (CKD) or serum creatinine and cystatin
C levels to estimate the risk associated with declining kidney func-
tion [1–3]. The ‘metabolic syndrome’ was identiﬁed as a complex
disorder deﬁned by a cluster of interconnected factors that in-
crease the risk of cardiovascular atherosclerotic diseases. The indi-
vidual components of the metabolic syndrome include threshold
levels for waist circumference (reﬂecting abdominal obesity),
plasma levels of triglycerides and HDL-cholesterol, arterial blood
pressure and fasting blood glucose level. Epidemiological studies
indicate that people with hallmarks of this syndrome are twice as
likely to develop heart disease and ﬁve times as likely to develop
diabetes as subjects without [4]. However, while the risk predic-
tion is applicable at the population level, it has arguably lower
predictive value in the individual patient. As a result, the
diagnostic value of the metabolic syndrome has been challenged,
and concerns have been raised on its utility in clinical practice
[5, 6]. In other words, while it is accepted that cardiovascular risk
factors represented within the metabolic syndrome tend to
cluster, the concept of whether this syndrome represents more
than the sum of its components has been recently disputed [5].
In CKD, abnormalities in circulating parameters of mineral
and bone metabolism (e.g. calcium, inorganic phosphorous,
vitamin D, PTH and FGF23) are frequently present and
associated with adverse clinical outcomes far beyond renal os-
teodystrophy. In 2006, these mineral and bone disorders
(MBD) of CKD patients have been suggested to represent a
speciﬁc entity, named CKD-MBD [7]. The aim of this paper is
to scrutinize if CKD-MBD qualiﬁes as a ‘true’ syndrome (by
examining to what extent it characterizes a distinct clinical
condition, apart from CKD per se).
DEFINITION OF CKD-MBD
Disorders of mineral metabolism and bone disease are com-
mon complications in CKD patients, and they are associated
with increased morbidity and mortality and decreased quality
of life. There is an increasing body of convincing evidence
suggesting that these disorders are causally related to numer-
ous adverse clinical outcomes, in particular cardiovascular
disease and increased fracture risk. In December 2004, it was
the opinion of the Board of Directors of NKF/K-DOQI™
guidelines (National Kidney Foundation/Kidney-Dialysis
Outcome Quality Initiative) that the absence of a precise ter-
minology and uniform classiﬁcation of these abnormalities
hampered communication and comparison of reported re-
search results. The Board of Directors of KDIGO thus chose to
address this deﬁcit as a priority action item. As a ﬁrst step, a
Controversies Conference of international experts was con-
vened in September 2005 to develop a consensus on a clear
deﬁnition and improved classiﬁcation scheme based on readily
available clinical parameters. This would serve to enhance
communication and direction of future research and form the
basis of evidence-based clinical practice guidelines for the care
of CKD patients affected with disordered mineral and bone
metabolism. The major goals of this 2005 meeting were to
(i) develop the evidentiary basis of the proposed recommen-
dations; and (ii) update the NKF/K-DOQI (National Kidney
Foundation/Kidney-Dialysis Outcome Quality Initiative)
Clinical Practice Guidelines for Bone Metabolism and Disease
in Chronic Kidney Disease that were published in 2003 and
frame them within the new deﬁnitions and classiﬁcations.
As a result of the conference, a position statement was
adopted introducing the new CKD-MBD condition, with the
following recommendations: (A) The term ‘renal osteodystro-
phy’, until then interchangeably employed to indicate the con-
dition of secondary hyperparathyroidism in uraemia, should
be used exclusively to deﬁne alterations in bone morphology
and bone metabolism associated with CKD. Moreover, the
deﬁnitive diagnosis of renal osteodystrophy should only be
made by bone biopsy followed by standardized bone histomor-
phometry analysis using a uniﬁed classiﬁcation system that in-
cludes parameters of turnover, mineralization and volume
(TMV classiﬁcation). (B) In addition, the new term CKD-
MBD should be used to describe broader clinical disorders
that develop as a consequence of CKD-related systemic altera-
tions in mineral and bone metabolism (Figure 1). These sys-
temic disturbances may manifest themselves by the presence
of any one or a combination of the following three conditions:
(i) laboratory abnormalities of calcium, inorganic phosphorus,
PTH or vitamin D (Figure 2); (ii) bone abnormalities in turn-
over, mineralization, volume, linear growth or strength
(Figure 3) and (iii) calciﬁcation of the vasculature or other soft
tissues (Figure 4). Based on the presence or absence of any
combination of these three primary components, a potential
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observations, was also suggested [7]. The association between
bone and vascular pathology, dubbed ‘bone-vascular axis’ has
recently been described, and its interest has even extended to
other medical specialties [8, 9]. Indeed, the relationship
between biomarkers of bone health and vascular calciﬁcation
is a fascinating but complex phenomenon with many uncer-
tain causal links that still remain to be fully elucidated.
I S CKD-MBD REALLY A TRUE SYNDROME?
Before any attempt to answer the question whether or not
CKD-MBD completely qualiﬁes as a syndrome, it is mandatory
to reﬂect on why this qualiﬁcation might be of importance in
clinical practice. This may be illustrated by an example more
close to nephrology than the metabolic syndrome, i.e. the ne-
phrotic syndrome. It is clear that several glomerular diseases
can underlie the nephrotic syndrome. For many of these glo-
merular diseases, the co-occurrence of a full-blown nephrotic
syndrome is not a pre-requisite to establish the glomerular diag-
nosis. Nephrotic syndrome identiﬁes a clinical situation of
uniquely high risk for systemic (thrombosis) and renal
complications (high risk of progression to ESKD) and per se
dictates treatments that are independent of the cause(s) of the
same syndrome, i.e. intensive use of diuretics and prophylactic
anticoagulation in severe cases (serum albumin <2.0 or 2.5 g/
dL). Thus, there are at least two good reasons why the nephrotic
syndrome qualiﬁes as a syndrome: prognosis and therapy.
In parallel, diagnosing the co-occurrence of CKD-MBD
F IGURE 2 : Thyroid gland B-mode ultrasonography revealing para-
thyroid gland hypertrophy of the right upper gland in a dialysis
patient with uncontrolled hyperparathyroidism: the parathyroid
gland is easily distinguishable as positioned behind the thyroid, oval
in shape, with a hypoechoic pattern, when compared with the neigh-
bouring tissue of the thyroid gland.
F IGURE 1 : CKD-MBD represents a synopsis of three closely
related disease conditions: laboratory abnormalities indicative of dis-
turbed bone and mineral metabolism; renal osteodystrophy summar-
izing the variety of bone lesion subtypes occurring in CKD;
cardiovascular disease representing accelerated arteriosclerosis, left
ventricular hypertrophy and a variety of additional pathologies in the
vasculature and the heart in patients with CKD.
F IGURE 3 : Bone histology from iliac crest biopsy: Goldner staining
revealing mixed uraemic osteodystrophy characterized by high cellu-
lar activity with osteoclastic giant cells in resorption lacunae, osteoid
accumulation (red areas) and peritrabecular ﬁbrosis (courtesy of Dr
Gabriele Lehmann, Jena, Germany)
F IGURE 4 : Ex vivo photograph of an explanted aortic valve due to
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components, besides reduced renal function as reﬂected by de-
clined GFR per se, may require speciﬁc interventions of its
several components, that in itself may improve outcome.
However, to deﬁne CKD-MBD as a true ‘syndrome’, it is
necessary to consider if it characterizes a speciﬁc complication
of CKD, and we will try to do this by answering the following
three questions.
The ‘ﬁrst question’ is, whether MBD occurring in the fra-
mework of CKD is a special condition in terms of diagnosis,
prognosis and treatment. According to its deﬁnition, the three
components of CKD-MBD appear to be well deﬁned and
easily recognizable (see Figure 1). Therefore, while the diagno-
sis of CKD per se is straightforward and based on the recently
reviewed international criteria of serum creatinine and albu-
minuria [3], this does not hold true for all components of
CKD-MBD. While assessment of both mineral disorders
(based on laboratory derangements in e.g. calcium, inorganic
phosphorous, PTH, vitamin D, total and bone-speciﬁc alkaline
phosphatases, and potentially also FGF23 and osteocalcin)
and vascular or ectopic soft tissue calciﬁcation (based on in-
strumental tests) are easily attainable, bone disease is less easy
to diagnose. Since CKD-MBD is deﬁned by the presence of ab-
normalities in any of the three components by which it is
deﬁned, diagnosis can be regarded as relatively straightforward
but easily missed when histological deﬁned bone disease is the
major or sole component. In contrast to the diagnosis of
CKD-MBD, the correct prognosis and treatment of this puta-
tive syndrome is much more complex. Several large observa-
tional studies indicate the importance of serum phosphorus
control during CKD and how its control leads to a favourable
CKD-MBD prognosis [10–12]. Furthermore, the importance
of monitoring serum phosphorus control has also been for-
mally acknowledged in the recent KDIGO guidelines. Follow-
ing a successful diagnosis of CKD-MBD, current therapeutic
approaches in the later stages of CKD before dialysis include
dietary phosphate restriction or oral phosphate binder use or
1,25D treatment to improve 1,25D deﬁciency and SHPT [13].
Use of phosphate binders and vitamin D activators has been
well documented; however, evidence is mainly based on large
epidemiological studies [14–18]. There is a concerning lack of
randomized, controlled trials examining the effect of a speciﬁc
therapy on prognostic and/or survival in this patient cohort
[19]. In summary to the original question, while the diagnosis
of CKD-MBD can be regarded as relatively simple, the prog-
nosis and therapeutic management of these patients still
remain a complex task.
The ‘second question’ is, whether there is an association
between CKD and MBD in determining the risk for cardiovas-
cular complications and CKD progression or bone outcomes.
To address this, we need to establish whether the combined
risk by CKD and MBD exceeds the risk predicted separately
by the two components of the purported syndrome. From a
clinical point of view, having the full-blown syndrome would
intuitively be worse than having a single component. Numer-
ous epidemiological studies associated all individual com-
ponents of CKD-MBD (laboratory abnormalities, bone disease
and cardiovascular disease) to clinical outcome parameters,
including mortality, even after correcting for renal function
using estimated GFR. Moreover, several basic research studies
have provided compelling evidence on a mechanism that may
underlie potential causality between CKD-MBD components
and disturbed outcome. However, since the concept of CKD-
MBD was launched, no study has attempted to verify the
relationship between any quantiﬁable levels of all its individual
components (as a composite risk score) with clinical outcome.
Furthermore, derangements in either direction (above or
below target range resulting in J-curve or U-curve associ-
ations) can imply an increase in relative risk, making it even
more challenging to ascribe a weight to a single deranged com-
ponent. Finally, the different components may indicate a
different risk weight: would we count more for a fracture com-
pared with raised serum phosphorous? Is the presence of a
fracture worse with low or with high PTH levels? In summary,
the question of added risk due to the presence of CKD-MBD
is afﬁrmative on a qualitative level, but is only based on histori-
cal cohort analyses. Currently, there is no clue that points to
graded effects of more severe CKD-MBD. It is critical that we
do not risk going down the road taken by the metabolic syn-
drome, where the existence of multiple deﬁnitions has led to
confusion, resulting in many studies and research papers com-
paring the merits of each deﬁnition, as opposed to focussing
on therapeutic management [6, 20].
A ‘third question’ is should the identiﬁcation of each single
component alone or in the setting of CKD-MBD affect thera-
peutic or clinical decision making? Treating each of the
components separately (e.g. correcting hyperphosphatemia re-
gardless of its effects on other components) is not expected to
carry the most beneﬁcial outcomes. This issue is even compli-
cated by the fact that targeting one component, for instance
the restoration of vitamin D deﬁciency, may aggravate another,
such as phosphate burden. Rather, a well-balanced and CKD-
MBD-multi-component-based approach is conceivably the
best method to make optimal therapeutic strategies. As an
example the approach to secondary hyperparathyroidism may
be quite different if also circulating levels of mineral biochemi-
cal markers, vitamin D status, presence or absence of extra-
skeletal calciﬁcations, and bone histomorphometry are taken
into account. So the answer to this third question appears to
be afﬁrmative, but evidence that such an approach improves
outcome is lacking, and a challenging trial target for the
future. Actually, almost all single-drug/single-intervention ap-
proaches in prospective studies on hard-outcomes in ESRD
have not been successful so far, and a multi-faceted/combined
CKD-MBD approach is probably needed. The only exception
to this lack of evidence comes from studies targeting the
disease entity formerly denominated.
DISCUSSION: WHERE DO WE STAND?
After the deﬁnition of CKD-MBD in 2006 [7], numerous
guidelines have been published with recommended biochemi-
cal targets and therapeutic strategies aimed at obtaining a
good clinical control of the condition [21]. Furthermore,
almost every National Society of Nephrology considered it
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[22–24]. Thus, the overall impact of the introduction of the
concept ‘CKD-MBD’ in the nephrology community has been
both sustained and impressive. Not surprisingly, the resulting
discussion has been centred on the applicability of the rec-
ommended biochemical targets, their reliability as surrogate
markers of outcome and the probability that novel therapeutic
approaches could actually result in the improvement of clini-
cally important outcomes, such as cardiovascular compli-
cations and mortality. It is interesting, however, to note that
few, if any, previous position statements have questioned the
justiﬁcation of the establishment and creation of a ‘new’
disease entity.
The European Renal Association–European Dialysis Trans-
plantation Association (ERA-EDTA) has recently founded a
scientiﬁc working group on CKD-MBD, because of the poten-
tial beneﬁcial impact of increased awareness of these disturbed
components, but also because ERA-EDTA recognizes the huge
scientiﬁc efforts that are required to bridge enormous gaps in
knowledge and bring this to the bedside of patients with CKD.
As a scientiﬁc working group, we believe that CKD-MBD is
most likely to be of importance in terms of added risk to CKD
patients, and that this additional risk can be targeted. Indeed,
as discussed above, in CKD patients, the presence of CKD-
MBD can be deﬁned by easily accessible diagnostic criteria
(with the exception of bone biopsy). However, the proof that
individual CKD-MBD components determine synergistically
clinical outcomes is lacking (e.g. can the severity and presence
of individual components of CKD-MBD assemble to a com-
posite risk marker with additive predictive power). Moreover,
it remains to be proven that treatment decisions based on
sound biological principles and surrogate markers of CKD-
MBD will translate into any detectable clinical beneﬁt. Indeed,
the recently published EVOLVE study [19] in which cinacalcet
use was compared with conventional therapy, based mostly on
vitamin D receptor activators (VDRA) in haemodialysis sub-
jects with hyperparathyroidism, did not demonstrate a survival
beneﬁt in its primary unadjusted intention to treat analysis. In
summary, our current opinion is, which CKD-MBD may have
the potential to be deﬁned as a true syndrome; however, it has
not yet been demonstrated as having additive predictive value
of its individuals components and still remains unproven that
it is a modiﬁable risk factor.
CKD-MBD: HOW TO PROCEED?
As a working group, we would like to launch a call for prog-
nostic and therapeutic studies that should be performed in
order to progress on these issues, which may lead to CKD-
MBD acquiring status as a syndrome. More important than
this status would be the acknowledgement that speciﬁc target-
ing CKD-MBD improves outcome. Prior to that, a validated
scoring system is required to quantify severity of CKD-MBD
and its subsequent improvement after targeted CKD-MBD
therapy.
The aim of this present paper was to recognize strengths
and weaknesses of the concept of CKD-MBD and to discuss
whether it should be considered a syndrome. The presence and
diagnosis of CKD-MBD should prompt speciﬁc interventions
targeted towards reducing the burden of CKD-MBD-related
outcomes like fractures, calciphylaxis and arterial calciﬁcations.
In our opinion, clinical practice might beneﬁt from moving
from a single-risk factor therapeutic strategy to a multiple-risk
factor or a single omni-comprehensive CKD-MBD score ap-
proach, but this position should be based on future clinical
trials. This global–multiple therapeutic approach to treat several
components of CKD-MBD, which is an additional argument to
consider CKD-MBD as a syndrome, should be tested by new
well-designed, randomized trials. Furthermore, the deﬁnition of
a grading system for CKD-MBDmay also provide opportunities
for patient stratiﬁcation (possible less heterogeneous subcate-
gories of CKD-MBD) and improvement in design of future
multi-target randomized clinical trials.
As a ﬁnal note of caution, we must be aware that CKD-
MBD is only one of several potential clinical syndromes
associated with CKD and exacerbated cardiovascular risk.
CKD-MBD is somehow unique in that either too low or too
high derangements can have deleterious effects. The optimal
metabolic balance to prevent cardiovascular risk remains to be
deﬁned and is expected to vary depending on CKD stage. Re-
gardless, the corroboration of CKD-MBD as a distinct entity
will likely increase our current knowledge in the ﬁeld, promote
early identiﬁcation of patients exposed to CKD-MBD risk and
ultimately generate more effective therapeutic strategies. Fur-
thermore, the deﬁnition of CKD-MBD could next be reﬁned
in the future, by taking into account other components, like
nutrition, inﬂammation, and/or other still incompletely un-
derstood endocrine functions of bone.
CONCLUSIONS
CKD-MBD does not currently fulﬁl all of the essential require-
ments of a true syndrome since the added value of the CKD-
MBD deﬁnition compared with its individual parts is still
undetermined. Moreover, additional work is warranted to
demonstrate that it is truly a modiﬁable risk factor. However,
there is a sound biological basis for the premise that CKD-
MBD is a distinct complication that can accompany CKD and
that it accelerates other comorbidities and leads to new com-
plications that would not have occurred in the absence of
CKD-MBD. Moreover, there is a striking consistency in epide-
miological data supporting an independent role of CKD-MBD
in the development of clinically relevant outcomes. We cur-
rently have several effective tools at our disposal, which can
ameliorate or modify the metabolic disturbances of CKD-
MBD. To conclude, since CKD-MBD may not presently
meet all the criteria necessary for it to be accepted as a syn-
drome (but is deﬁnitely worthy of further research), we
suggest that its continued currency adds signiﬁcantly to clini-
cal and experimental thinking and practice. Moreover, despite
all we have learned about this putative syndrome, we have
been left with hypotheses about how to treat patients. So a
global–multiple therapeutic approach to treat simultaneously
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